Related Experiment Videos
Streptozotocin upregulates GAD67 expression in MIN6N8a mouse beta cells
Sung-E Choi1, Hye-Lim Noh, Hyeon-Man Kim
1Institute for Medical Science, Ajou University School of Medicine, Suwon, Kyunggi-do, Republic of Korea.
Journal of Autoimmunity
|October 9, 2002
Summary
Low-dose streptozotocin (STZ) increases GAD67 expression in mouse beta cells. This occurs via oxidative stress activating NF-kappaB and p53, highlighting a mechanism for GAD autoantigen regulation in diabetes.
Area of Science:
- Immunology
- Endocrinology
- Molecular Biology
Background:
- Glutamic acid decarboxylase (GAD) is a key autoantigen in autoimmune insulin-dependent diabetes mellitus (IDDM).
- Mechanisms controlling GAD expression in pancreatic beta cells remain unclear.
Purpose of the Study:
- To investigate the impact of streptozotocin (STZ) on GAD67 expression in mouse beta cells.
- To elucidate the molecular pathways involved in STZ-induced GAD67 upregulation.
Main Methods:
- MIN6N8a mouse beta cells were treated with STZ.
- GAD67 mRNA and protein levels were assessed.
- The roles of p53, NF-kappaB, oxidative stress, and NAD+ were examined.
Main Results:
- STZ treatment significantly increased GAD67 mRNA expression (5-6 fold).
- STZ elevated p53 levels and activated NF-kappaB.
- N-acetyl cysteine (NAC) abolished STZ effects, indicating oxidative stress involvement.
- NAD+ partially reduced GAD67 upregulation.
Conclusions:
- Low-dose STZ upregulates GAD67 expression in mouse beta cells.
- NF-kappaB activation, driven by oxidative stress, is crucial for this upregulation.
- These findings suggest stimuli activating NF-kappaB may increase GAD autoantigen expression in beta cells.